ClinicalTrials.gg
CompletedNCT05620836STOP-HS2Updated Nov 5, 2026Results posted

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

A Phase 3 interventional study of Povorcitinib and Placebo in Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation. Completed at 101 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Updated Nov 5, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
619
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Hidradenitis Suppurativa by Incyte Corporation — 3 open to participants now, 6 under way, 4 of them phase 3. Hidradenitis Suppurativa · Incyte Corporation.

Enrollment
Largest of 12
619 · median 391
Started
2023
the only one that year
Phase 3
6 of 12
1 open now
Registered
4th of 12
by date

Among the 12 studies in Hidradenitis Suppurativa by Incyte Corporation, this one has the largest enrollment, is the only one that started in 2023, is one of 6 in phase 3, and was the 4th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

3 of the 12 studies in Hidradenitis Suppurativa by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hidradenitis Suppurativa by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.

03

Conditions studied

  • Hidradenitis Suppurativa (HS)

Keywords

  • Hidradenitis Suppurativa
  • HS
  • INCB054707
  • Povorcitinib
  • Acne inversa
  • Hidradenitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants ≥ 18 years of age.
  • Diagnosis of moderate to severe HS ≥ 3 months prior to Screening visit.
  • HS lesions present in ≥ 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the Screening and Baseline visits.
  • Total abscess and inflammatory nodule (AN) count ≥ 5 at both the Screening and Baseline visits.
  • History of inadequate response to an appropriate course of at least 1 conventional systemic therapy for HS (or demonstrated intolerance to, or have a to, a conventional systemic therapy for HS)
  • Agree to not use certain topical antiseptics on the areas affected by HS lesions during the placebo-controlled period.
  • Willingness to avoid pregnancy or fathering children.
  • Other inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Draining tunnel count of > 20 at Screening or Baseline visits.
  • Women who are pregnant (or who are considering pregnancy) or breastfeeding.
  • Medical history including thrombocytopenia, coagulopathy or dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; .
  • Evidence of infection with TB, , or .
  • History of failure to JAK inhibitor treatment of any inflammatory disease.
  • Laboratory values outside of the protocol-defined ranges.
  • Other exclusion criteria apply.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
619 participants (actual)

Study arms

  • Experimental
    Povorcitinib Dose A

    Participants will receive Povorcitinib Dose A for 54 weeks.

    Drug: Povorcitinib

  • Experimental
    Povorcitinib Dose B

    Participants will receive Povorcitinib Dose B for 54 weeks.

    Drug: Povorcitinib

  • Placebo comparator
    Placebo

    Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.

    Drug: Placebo

Interventions

  • Oral, Tablet

    Also known as: INCB054707

  • DrugPlacebo

    Oral, Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 12

    HiSCR50 is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: Baseline; Week 12

Secondary outcomes

  1. Percentage of Participants Who Achieved HiSCR75 at Week 12

    HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: Baseline; Week 12

  2. Percentage of Participants With Flare by Week 12

    Participants who experienced at least 1 flare over 12 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.

    Time frame: Baseline; Week 12

  3. Percentage of Participants With at Least a 3-point Decrease in Skin Pain Numerical Rating Scale (NRS) Score at Week 12 Among Participants With a Baseline Skin Pain NRS Score ≥3

    Participants with a Skin Pain score of at least 3 at baseline and who experienced at least a 3-point decrease in Skin Pain score at Week 12, relative to baseline, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain).

    Time frame: Baseline; Week 12

  4. Percentage of Participants Who Achieved Skin Pain NRS30 at Week 12 Among Participants With a Baseline Skin Pain NRS Score of at Least 3

    Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 12, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain). analyzed.

    Time frame: Baseline; Week 12

  5. Percentage of Participants With at Least a 4-point Increase From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 12

    Participants with a baseline FACIT-F score ≤48 and who experienced at least a 4-point increase in FACIT-F score at Week 12, relative to baseline, were assessed. The FACIT-F scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days, with scores for each item ranging from 0 (worst fatigue) to 4 (no fatigue). The total score is a sum of the 13 item scores and ranges from 0 (worst fatigue) to 52 (no fatigue).

    Time frame: Baseline; Week 12

  6. Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

    The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life.

    Time frame: Baseline; up to Week 54

  7. Mean Change From Baseline in DLQI Score at Each Visit During the Extension Period

    The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life.

    Time frame: Baseline; up to Week 54

  8. Mean Change From Baseline in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

    Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; up to Week 54

  9. Mean Change From Baseline in Abscess Count at Each Visit During the Extension Period

    Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; up to Week 54

  10. Percentage Change From Baseline (PCFB) in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

    Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

    Time frame: Baseline; up to Week 54

  11. Percentage Change From Baseline in Abscess Count at Each Visit During the Extension Period

    Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

    Time frame: Baseline; up to Week 54

  12. Mean Change From Baseline in Inflammatory Nodule Count at Each Visit at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

    Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; up to Week 54

  13. Mean Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period

    Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; up to Week 54

  14. Percentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

    Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

    Time frame: Baseline; up to Week 54

  15. Percentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period

    Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

    Time frame: Baseline; up to Week 54

  16. Mean Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

    Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; up to Week 54

  17. Mean Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period

    Change from baseline was calculated as the post-baseline value minus the baseline value.

    Time frame: Baseline; up to Week 54

  18. Percentage Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

    Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

    Time frame: Baseline; up to Week 54

  19. Percentage Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period

    Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

    Time frame: Baseline; up to Week 54

  20. Percentage of Participants Who Achieved HiSCR50 at Week 24 for Participants Who Took Only Povorcitinib

    HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: Baseline; Week 24

  21. Percentage of Participants Who Achieved HiSCR50 at Week 24 During the Extension Period

    HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: Baseline; Week 24

  22. Percentage of Participants Who Achieved HiSCR75 at Week 24 for Participants Who Took Only Povorcitinib

    HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: Baseline; Week 24

  23. Percentage of Participants Who Achieved HiSCR75 at Week 24 During the Extension Period

    HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: Baseline; Week 24

  24. Percentage of Participants With Flare by Week 24 for Participants Who Took Only Povorcitinib

    Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.

    Time frame: Baseline; up to Week 24

  25. Percentage of Participants With Flare by Week 24 During the Extension Period

    Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.

    Time frame: Baseline; up to Week 24

  26. Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib

    Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.

    Time frame: Baseline; Week 24

  27. Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3

    Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.

    Time frame: Baseline; Week 24

  28. Percentage of Participants Who Achieved HiSCR50 at Week 54 for Participants Who Took Only Povorcitinib

    HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: Baseline; Week 54

  29. Percentage of Participants Who Achieved HiSCR50 at Week 54 During the Extension Period

    HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: Baseline; Week 54

  30. Percentage of Participants Who Achieved HiSCR75 at Week 54 for Participants Who Took Only Povorcitinib

    HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: Baseline; Week 54

  31. Percentage of Participants Who Achieved HiSCR75 at Week 54 During the Extension Period

    HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: Baseline; Week 54

  32. Percentage of Participants With Flare by Week 54 for Participants Who Took Only Povorcitinib

    Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.

    Time frame: Baseline; up to Week 54

  33. Percentage of Participants With Flare at Week 54 During the Extension Period

    Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.

    Time frame: Baseline; up to Week 54

  34. Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib

    Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.

    Time frame: Baseline; Week 54

  35. Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3

    Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.

    Time frame: Baseline; Week 54

  36. Percentage of Participants Who Achieved Maintenance of HiSCR50 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib

    Maintenance of response is defined as achieving HiSCR50 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: up to 42 weeks (from end of Week 12 to end of Week 54)

  37. Percentage of Participants Who Achieved Maintenance of HiSCR75 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib

    Maintenance of response is defined as achieving HiSCR75 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

    Time frame: up to 42 weeks (from end of Week 12 to end of Week 54)

  38. Placebo-controlled Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.

    Time frame: up to Week 16

  39. Placebo-controlled Period: Number of Participants With ≥Grade 3 TEAEs

    A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to Week 16

  40. Extension Period: Number of Participants With TEAEs

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.

    Time frame: up to 46 weeks (from end of Week 12 to end of Week 58)

  41. Extension Period: Number of Participants With ≥Grade 3 TEAEs

    A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to 46 weeks (from end of Week 12 to end of Week 58)

  42. Overall Study Period: Number of Participants Who Took Only Povorcitinib With TEAEs

    An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.

    Time frame: up to Week 58

  43. Overall Study Period: Number of Participants Who Took Only Povorcitinib With ≥Grade 3 TEAEs

    A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

    Time frame: up to Week 58

07

Results

Posted Nov 5, 2026

Participant flow

12-Week Placebo-Controlled Period
Participant flow — 12-Week Placebo-Controlled Period
MilestonePlaceboPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QDPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Started20300208208
Completed18300185187
Not completed20002321
Withdrew: Lost to follow-up70065
Withdrew: Withdrawal by subject50077
Withdrew: Adverse event30063
Withdrew: Physician decision10032
Withdrew: Protocol deviation30011
Withdrew: Lack of efficacy10000
Withdrew: Sponsor decision00001
Withdrew: Worsening of disease00001
Withdrew: Not treated00001
42-Week Extension Period
Participant flow — 42-Week Extension Period
MilestonePlaceboPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QDPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Started09092184188
Completed05656114124
Not completed034367064
Withdrew: Withdrawal by subject022132422
Withdrew: Adverse event0313912
Withdrew: Lack of efficacy0351512
Withdrew: Lost to follow-up032127
Withdrew: Protocol deviation02167
Withdrew: Physician decision01130
Withdrew: Sponsor decision00100
Withdrew: Pregnancy00010
Withdrew: Extended travel00001
Withdrew: Non-compliance with study drug00001
Withdrew: Captured as "early termination" in database00001
Withdrew: Investigational product interrupted for longer than 28 days00001

Outcome measures

PrimaryPercentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 12

HiSCR50 is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
Baseline; Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 12
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 1228.6 (22.5 to 35.3)42.3 (35.5 to 49.3)42.3 (35.5 to 49.3)
Statistical analysis
  • Placebo vs Povorcitinib 45 mg QD · Cochran-Mantel-Haenszel · p = 0.0035 · Odds ratio (or): 1.8 · 95% CI 1.2 to 2.8stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 45 mg QD · Difference in response rate: 13.8 · 95% CI 4.7 to 23.0Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
  • Placebo vs Povorcitinib 75 mg QD · Cochran-Mantel-Haenszel · p = 0.0033 · Odds ratio (or): 1.9 · 95% CI 1.2 to 2.8stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 75 mg QD · Difference in response rate: 13.8 · 95% CI 4.7 to 22.9Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
SecondaryPercentage of Participants Who Achieved HiSCR75 at Week 12

HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
Baseline; Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HiSCR75 at Week 12
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants Who Achieved HiSCR75 at Week 1213.3 (9.0 to 18.8)25.5 (19.7 to 32.0)28.4 (22.3 to 35.0)
Statistical analysis
  • Placebo vs Povorcitinib 45 mg QD · Cochran-Mantel-Haenszel · p = 0.0017 · Odds ratio (or): 2.2 · 95% CI 1.3 to 3.8stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 45 mg QD · Difference in response rate: 12.3 · 95% CI 4.7 to 19.8Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
  • Placebo vs Povorcitinib 75 mg QD · Cochran-Mantel-Haenszel · p = 0.0002 · Odds ratio (or): 2.6 · 95% CI 1.6 to 4.4stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 75 mg QD · Difference in response rate: 15.1 · 95% CI 7.5 to 22.7Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
SecondaryPercentage of Participants With Flare by Week 12

Participants who experienced at least 1 flare over 12 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.

Time frame:
Baseline; Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Flare by Week 12
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants With Flare by Week 1233.5 (27.0 to 40.4)21.6 (16.2 to 27.9)20.7 (15.4 to 26.8)
Statistical analysis
  • Placebo vs Povorcitinib 45 mg QD · Cochran-Mantel-Haenszel · p = 0.0067 · Odds ratio (or): 0.5 · 95% CI 0.4 to 0.8stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 45 mg QD · Difference in response rate: -11.9 · 95% CI -20.5 to -3.4Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
  • Placebo vs Povorcitinib 75 mg QD · Cochran-Mantel-Haenszel · p = 0.0032 · Odds ratio (or): 0.5 · 95% CI 0.3 to 0.8stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 75 mg QD · Difference in response rate: -12.9 · 95% CI -21.3 to -4.4Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
SecondaryPercentage of Participants With at Least a 3-point Decrease in Skin Pain Numerical Rating Scale (NRS) Score at Week 12 Among Participants With a Baseline Skin Pain NRS Score ≥3

Participants with a Skin Pain score of at least 3 at baseline and who experienced at least a 3-point decrease in Skin Pain score at Week 12, relative to baseline, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain).

Time frame:
Baseline; Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 3-point Decrease in Skin Pain Numerical Rating Scale (NRS) Score at Week 12 Among Participants With a Baseline Skin Pain NRS Score ≥3
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants With at Least a 3-point Decrease in Skin Pain Numerical Rating Scale (NRS) Score at Week 12 Among Participants With a Baseline Skin Pain NRS Score ≥39.3 (5.2 to 15.1)29.1 (22.3 to 36.7)22.0 (15.8 to 29.3)
Statistical analysis
  • Placebo vs Povorcitinib 45 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.1 · 95% CI 2.1 to 7.8stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 45 mg QD · Difference in response rate: 20.0 · 95% CI 11.7 to 28.3Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
  • Placebo vs Povorcitinib 75 mg QD · Cochran-Mantel-Haenszel · p = 0.0015 · Odds ratio (or): 2.9 · 95% CI 1.5 to 5.7stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 75 mg QD · Difference in response rate: 13.1 · 95% CI 5.3 to 21.0Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
SecondaryPercentage of Participants Who Achieved Skin Pain NRS30 at Week 12 Among Participants With a Baseline Skin Pain NRS Score of at Least 3

Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 12, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain). analyzed.

Time frame:
Baseline; Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 12 Among Participants With a Baseline Skin Pain NRS Score of at Least 3
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 12 Among Participants With a Baseline Skin Pain NRS Score of at Least 317.9 (12.1 to 24.9)40.6 (33.0 to 48.5)37.7 (30.2 to 45.8)
Statistical analysis
  • Placebo vs Povorcitinib 45 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.1 · 95% CI 1.8 to 5.2stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 45 mg QD · Difference in response rate: 22.7 · 95% CI 13.0 to 32.5Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
  • Placebo vs Povorcitinib 75 mg QD · Cochran-Mantel-Haenszel · p = 0.0001 · Odds ratio (or): 2.7 · 95% CI 1.6 to 4.6stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 75 mg QD · Difference in response rate: 19.9 · 95% CI 10.0 to 29.7Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
SecondaryPercentage of Participants With at Least a 4-point Increase From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 12

Participants with a baseline FACIT-F score ≤48 and who experienced at least a 4-point increase in FACIT-F score at Week 12, relative to baseline, were assessed. The FACIT-F scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days, with scores for each item ranging from 0 (worst fatigue) to 4 (no fatigue). The total score is a sum of the 13 item scores and ranges from 0 (worst fatigue) to 52 (no fatigue).

Time frame:
Baseline; Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 4-point Increase From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 12
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants With at Least a 4-point Increase From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 1232.145.146.1
Statistical analysis
  • Placebo vs Povorcitinib 45 mg QD · Cochran-Mantel-Haenszel · p = 0.0100 · Odds ratio (or): 1.7 · 95% CI 1.1 to 2.6stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 45 mg QD · Difference in response rate: 12.9 · 95% CI 3.2 to 22.7Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
  • Placebo vs Povorcitinib 75 mg QD · Cochran-Mantel-Haenszel · p = 0.0050 · Odds ratio (or): 1.8 · 95% CI 1.2 to 2.8stratified by randomization stratification factors (baseline abscess, inflammatory nodule, and draining tunnel count and previous treatment of HS)
  • Placebo vs Povorcitinib 75 mg QD · Difference in response rate: 14.1 · 95% CI 4.3 to 23.8Response rate was stratum-adjusted, and 95% confidence interval was based on Mantel-Haenszel stratum weights.
SecondaryMean Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · scores on a scale
Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
scores on a scalePlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Baseline12.52 ± 7.07413.88 ± 7.50012.86 ± 6.912
Change from Baseline at Week 3-1.40 ± 4.435-3.88 ± 5.253-3.67 ± 5.425
Change from Baseline at Week 6-1.12 ± 5.703-3.84 ± 6.526-4.09 ± 5.814
Change from Baseline at Week 9-1.89 ± 5.712-3.39 ± 6.431-3.70 ± 5.832
Change from Baseline at Week 12-1.22 ± 5.981-3.80 ± 6.976-4.04 ± 6.053
Change from Baseline at Week 15—-4.45 ± 6.500-3.97 ± 6.374
Change from Baseline at Week 18—-4.10 ± 6.974-4.08 ± 6.333
Change from Baseline at Week 24—-4.51 ± 7.163-4.66 ± 6.634
Change from Baseline at Week 30—-5.52 ± 7.377-4.03 ± 6.540
Change from Baseline at Week 36—-5.25 ± 7.086-4.11 ± 6.721
Change from Baseline at Week 42—-5.37 ± 6.943-4.31 ± 6.015
Change from Baseline at Week 48—-5.41 ± 7.129-5.53 ± 5.910
Change from Baseline at Week 54—-5.77 ± 7.026-5.08 ± 6.478
SecondaryMean Change From Baseline in DLQI Score at Each Visit During the Extension Period

The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · scores on a scale
Mean Change From Baseline in DLQI Score at Each Visit During the Extension Period
scores on a scalePlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Baseline12.29 ± 6.79812.24 ± 6.990
Change from Baseline at Week 15-4.67 ± 4.698-4.53 ± 5.594
Change from Baseline at Week 18-4.23 ± 5.789-4.47 ± 6.584
Change from Baseline at Week 24-4.38 ± 5.802-4.14 ± 6.594
Change from Baseline at Week 30-4.61 ± 5.552-4.76 ± 6.874
Change from Baseline at Week 36-5.27 ± 6.428-4.98 ± 6.131
Change from Baseline at Week 42-4.26 ± 7.287-5.78 ± 6.861
Change from Baseline at Week 48-3.41 ± 7.446-5.16 ± 7.093
Change from Baseline at Week 54-3.81 ± 7.307-5.26 ± 7.392
SecondaryMean Change From Baseline in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · abscesses
Mean Change From Baseline in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
abscessesPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Baseline2.53 ± 3.8132.07 ± 2.9371.86 ± 3.451
Change from Baseline at Week 3-0.25 ± 1.814-0.67 ± 1.983-0.34 ± 2.282
Change from Baseline at Week 6-0.46 ± 2.214-0.88 ± 2.279-0.54 ± 2.385
Change from Baseline at Week 9-0.59 ± 2.349-0.80 ± 2.424-0.50 ± 2.778
Change from Baseline at Week 12-0.70 ± 2.776-0.91 ± 2.788-0.64 ± 2.807
Change from Baseline at Week 15—-1.19 ± 2.733-0.77 ± 2.883
Change from Baseline at Week 18—-1.28 ± 2.751-0.84 ± 2.941
Change from Baseline at Week 24—-1.20 ± 2.820-0.86 ± 2.708
Change from Baseline at Week 30—-0.95 ± 3.167-0.97 ± 2.746
Change from Baseline at Week 36—-1.22 ± 3.031-0.90 ± 2.638
Change from Baseline at Week 42—-1.23 ± 3.267-0.66 ± 2.753
hange from Baseline at Week 48—-1.15 ± 3.508-0.91 ± 2.706
Change from Baseline at Week 54—-1.14 ± 3.318-0.85 ± 2.816
SecondaryMean Change From Baseline in Abscess Count at Each Visit During the Extension Period

Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · abscesses
Mean Change From Baseline in Abscess Count at Each Visit During the Extension Period
abscessesPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Baseline2.27 ± 3.0602.33 ± 3.835
Change from Baseline at Week 15-1.13 ± 2.487-1.19 ± 2.828
Change from Baseline at Week 18-1.13 ± 2.596-1.32 ± 3.218
Change from Baseline at Week 24-1.35 ± 2.575-1.29 ± 3.227
Change from Baseline at Week 30-1.20 ± 2.559-1.63 ± 3.376
Change from Baseline at Week 36-1.26 ± 2.737-1.45 ± 3.255
Change from Baseline at Week 42-1.18 ± 2.571-1.43 ± 3.827
Change from Baseline at Week 48-1.14 ± 2.719-1.18 ± 3.500
Change from Baseline at Week 54-1.41 ± 2.977-1.29 ± 3.530
SecondaryPercentage Change From Baseline (PCFB) in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · percentage change
Percentage Change From Baseline (PCFB) in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
percentage changePlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
PCFB at Week 3-16.48 ± 69.765-36.07 ± 60.391-19.38 ± 76.971
PCFB at Week 6-15.80 ± 79.791-46.22 ± 67.273-26.70 ± 70.464
PCFB at Week 9-20.57 ± 86.036-37.40 ± 89.384-34.40 ± 86.887
PCFB at Week 12-23.53 ± 100.116-42.65 ± 100.243-39.41 ± 82.637
PCFB at Week 15—-61.44 ± 60.692-39.29 ± 85.053
PCFB at Week 18—-58.15 ± 70.831-49.89 ± 80.331
PCFB at Week 24—-49.13 ± 65.103-36.46 ± 101.579
PCFB at Week 30—-34.15 ± 137.637-48.94 ± 86.763
PCFB at Week 36—-52.20 ± 97.432-54.58 ± 75.387
PCFB at Week 42—-68.18 ± 52.199-48.74 ± 74.659
PCFB at Week 48—-53.60 ± 74.782-58.87 ± 72.812
PCFB at Week 54—-62.89 ± 57.292-54.52 ± 79.562
SecondaryPercentage Change From Baseline in Abscess Count at Each Visit During the Extension Period

Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · percentage change
Percentage Change From Baseline in Abscess Count at Each Visit During the Extension Period
percentage changePlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
PCFB at Week 15-44.19 ± 96.423-45.15 ± 69.705
PCFB at Week 18-49.55 ± 63.816-45.87 ± 67.735
PCFB at Week 24-65.08 ± 49.248-43.81 ± 77.341
PCFB at Week 30-56.37 ± 95.535-59.79 ± 54.822
PCFB at Week 36-63.89 ± 70.178-57.50 ± 65.339
PCFB at Week 42-57.96 ± 75.045-54.29 ± 86.756
PCFB at Week 48-44.14 ± 109.130-43.42 ± 116.706
PCFB at Week 54-69.52 ± 64.592-41.98 ± 90.298
SecondaryMean Change From Baseline in Inflammatory Nodule Count at Each Visit at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · inflammatory nodules
Mean Change From Baseline in Inflammatory Nodule Count at Each Visit at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
inflammatory nodulesPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Baseline8.55 ± 5.3079.49 ± 7.80310.19 ± 7.685
Change from Baseline at Week 3-1.57 ± 3.877-2.68 ± 4.286-3.05 ± 4.307
Change from Baseline at Week 6-1.97 ± 4.486-3.66 ± 4.305-4.16 ± 5.392
Change from Baseline at Week 9-2.35 ± 4.814-4.35 ± 5.148-4.75 ± 6.237
Change from Baseline at Week 12-2.04 ± 5.534-4.58 ± 5.330-4.60 ± 5.006
Change from Baseline at Week 15—-5.38 ± 6.644-5.47 ± 5.926
Change from Baseline at Week 18—-5.35 ± 6.539-5.87 ± 6.378
Change from Baseline at Week 24—-5.50 ± 7.220-6.43 ± 6.925
Change from Baseline at Week 30—-5.59 ± 6.618-6.59 ± 7.791
Change from Baseline at Week 36—-5.29 ± 6.431-6.42 ± 7.259
Change from Baseline at Week 42—-5.61 ± 6.229-6.33 ± 7.864
Change from Baseline at Week 48—-5.42 ± 6.291-6.65 ± 7.257
Change from Baseline at Week 54—-5.48 ± 6.182-6.40 ± 7.429
SecondaryMean Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period

Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · inflammatory nodules
Mean Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period
inflammatory nodulesPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Baseline8.93 ± 5.6418.51 ± 5.119
Change from Baseline at Week 15-3.87 ± 4.747-3.95 ± 4.339
Change from Baseline at Week 18-4.36 ± 4.511-4.91 ± 4.336
Change from Baseline at Week 24-5.21 ± 4.698-4.85 ± 4.450
Change from Baseline at Week 30-5.43 ± 4.284-5.29 ± 5.214
Change from Baseline at Week 36-5.77 ± 5.634-5.31 ± 4.390
Change from Baseline at Week 42-5.26 ± 5.444-5.91 ± 5.783
Change from Baseline at Week 48-4.76 ± 6.954-5.51 ± 5.497
Change from Baseline at Week 54-5.05 ± 6.645-5.30 ± 4.072
SecondaryPercentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · percentage change
Percentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
percentage changePlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
PCFB at Week 3-19.15 ± 40.712-26.67 ± 45.067-30.34 ± 38.085
PCFB at Week 6-23.10 ± 55.564-37.49 ± 51.594-39.81 ± 46.070
PCFB at Week 9-25.92 ± 58.998-44.12 ± 48.143-47.56 ± 49.033
PCFB at Week 12-23.80 ± 62.444-47.61 ± 51.545-48.93 ± 47.827
PCFB at Week 15—-52.69 ± 45.812-54.51 ± 45.876
PCFB at Week 18—-53.12 ± 55.075-58.15 ± 43.417
PCFB at Week 24—-54.97 ± 61.697-62.27 ± 41.625
PCFB at Week 30—-56.22 ± 70.254-63.00 ± 45.082
PCFB at Week 36—-50.71 ± 98.451-63.66 ± 42.444
PCFB at Week 42—-58.02 ± 85.998-60.18 ± 53.924
PCFB at Week 48—-59.23 ± 90.813-64.79 ± 46.342
PCFB at Week 54—-56.95 ± 117.466-63.20 ± 45.420
SecondaryPercentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period

Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · percentage change
Percentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period
percentage changePlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
PCFB at Week 15-46.63 ± 53.532-46.51 ± 40.505
PCFB at Week 18-53.38 ± 50.552-59.03 ± 36.653
PCFB at Week 24-61.09 ± 41.037-56.66 ± 39.079
PCFB at Week 30-62.63 ± 45.226-61.73 ± 40.353
PCFB at Week 36-52.89 ± 123.853-64.27 ± 35.847
PCFB at Week 42-59.56 ± 54.000-70.21 ± 38.458
Change from Baseline at Week 48-41.81 ± 159.447-67.60 ± 46.289
PCFB at Week 54-60.30 ± 50.373-63.13 ± 40.078
SecondaryMean Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · draining tunnels
Mean Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
draining tunnelsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Baseline2.95 ± 3.3472.73 ± 3.1722.52 ± 2.976
Change from Baseline at Week 30.05 ± 1.753-0.54 ± 1.806-0.76 ± 2.225
Change from Baseline at Week 6-0.29 ± 2.082-0.87 ± 2.162-1.01 ± 2.351
Change from Baseline at Week 9-0.55 ± 2.208-0.88 ± 2.114-1.11 ± 2.282
Change from Baseline at Week 12-0.37 ± 2.366-1.09 ± 2.152-1.06 ± 2.089
Change from Baseline at Week 15—-1.19 ± 2.286-1.08 ± 2.295
Change from Baseline at Week 18—-1.21 ± 2.329-1.06 ± 2.208
Change from Baseline at Week 24—-1.21 ± 2.585-1.23 ± 2.325
Change from Baseline at Week 30—-1.18 ± 3.154-1.27 ± 2.149
Change from Baseline at Week 36—-1.31 ± 2.938-1.39 ± 2.140
Change from Baseline at Week 42—-1.43 ± 2.869-1.30 ± 2.382
Change from Baseline at Week 48—-1.55 ± 2.872-1.44 ± 2.336
Change from Baseline at Week 54—-1.67 ± 2.729-1.35 ± 2.416
SecondaryMean Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period

Change from baseline was calculated as the post-baseline value minus the baseline value.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · draining tunnels
Mean Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period
draining tunnelsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Baseline2.81 ± 3.5383.12 ± 3.251
Change from Baseline at Week 15-0.87 ± 2.552-1.18 ± 2.411
Change from Baseline at Week 18-0.98 ± 2.845-1.20 ± 2.366
Change from Baseline at Week 24-1.19 ± 2.775-1.05 ± 2.597
Change from Baseline at Week 30-1.34 ± 2.837-1.25 ± 2.717
Change from Baseline at Week 36-1.38 ± 2.352-1.04 ± 3.838
Change from Baseline at Week 42-1.52 ± 2.374-1.09 ± 3.180
Change from Baseline at Week 48-1.31 ± 2.866-1.38 ± 2.684
Change from Baseline at Week 54-1.18 ± 2.842-1.43 ± 2.579
SecondaryPercentage Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)

Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · percentage change
Percentage Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
percentage changePlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
PCFB at Week 3-1.37 ± 81.971-20.47 ± 55.834-27.03 ± 58.237
PCFB at Week 6-10.36 ± 101.112-36.80 ± 61.261-34.97 ± 70.126
PCFB at Week 9-23.10 ± 84.928-32.84 ± 63.624-43.36 ± 72.695
PCFB at Week 12-15.02 ± 91.581-42.88 ± 58.389-42.69 ± 64.219
PCFB at Week 15—-50.00 ± 58.914-42.25 ± 85.319
PCFB at Week 18—-47.44 ± 63.163-45.18 ± 72.834
PCFB at Week 24—-42.61 ± 75.780-52.04 ± 71.771
PCFB at Week 30—-31.11 ± 107.437-52.70 ± 81.691
PCFB at Week 36—-37.65 ± 106.728-58.46 ± 70.802
PCFB at Week 42—-44.69 ± 98.005-46.23 ± 118.337
PCFB at Week 48—-53.57 ± 63.118-56.05 ± 109.685
PCFB at Week 54—-57.71 ± 61.752-51.91 ± 130.770
SecondaryPercentage Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period

Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100.

Time frame:
Baseline; up to Week 54
Reported as:
Mean · percentage change
Percentage Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period
percentage changePlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
PCFB at Week 15-30.60 ± 102.030-43.81 ± 57.304
PCFB at Week 18-30.58 ± 149.719-46.06 ± 56.989
PCFB at Week 24-41.06 ± 107.121-34.02 ± 87.701
PCFB at Week 30-61.76 ± 62.225-56.13 ± 58.982
PCFB at Week 36-67.31 ± 50.116-52.72 ± 68.217
PCFB at Week 42-60.18 ± 75.984-39.03 ± 100.063
PCFB at Week 48-51.57 ± 69.588-49.85 ± 110.572
PCFB at Week 54-45.78 ± 80.657-48.12 ± 100.908
SecondaryPercentage of Participants Who Achieved HiSCR50 at Week 24 for Participants Who Took Only Povorcitinib

HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HiSCR50 at Week 24 for Participants Who Took Only Povorcitinib
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants Who Achieved HiSCR50 at Week 24 for Participants Who Took Only Povorcitinib—57.1 (49.1 to 64.9)57.9 (49.8 to 65.6)
SecondaryPercentage of Participants Who Achieved HiSCR50 at Week 24 During the Extension Period

HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HiSCR50 at Week 24 During the Extension Period
percentage of participantsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Percentage of Participants Who Achieved HiSCR50 at Week 24 During the Extension Period58.0 (46.5 to 68.9)56.3 (45.3 to 66.9)
SecondaryPercentage of Participants Who Achieved HiSCR75 at Week 24 for Participants Who Took Only Povorcitinib

HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HiSCR75 at Week 24 for Participants Who Took Only Povorcitinib
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants Who Achieved HiSCR75 at Week 24 for Participants Who Took Only Povorcitinib—37.3 (29.8 to 45.2)40.3 (32.6 to 48.3)
SecondaryPercentage of Participants Who Achieved HiSCR75 at Week 24 During the Extension Period

HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HiSCR75 at Week 24 During the Extension Period
percentage of participantsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Percentage of Participants Who Achieved HiSCR75 at Week 24 During the Extension Period38.3 (27.7 to 49.7)31.0 (21.5 to 41.9)
SecondaryPercentage of Participants With Flare by Week 24 for Participants Who Took Only Povorcitinib

Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.

Time frame:
Baseline; up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Flare by Week 24 for Participants Who Took Only Povorcitinib
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants With Flare by Week 24 for Participants Who Took Only Povorcitinib—17.8 (12.8 to 23.8)19.6 (14.4 to 25.7)
SecondaryPercentage of Participants With Flare by Week 24 During the Extension Period

Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.

Time frame:
Baseline; up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Flare by Week 24 During the Extension Period
percentage of participantsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Percentage of Participants With Flare by Week 24 During the Extension Period6.7 (2.5 to 14.1)5.4 (1.8 to 12.2)
SecondaryPercentage of Participants Who Achieved Skin Pain NRS30 at Week 24 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib

Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib—55.0 (45.7 to 64.1)61.5 (51.0 to 71.2)
SecondaryPercentage of Participants Who Achieved Skin Pain NRS30 at Week 24 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3

Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3
percentage of participantsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 365.5 (51.4 to 77.8)52.5 (39.1 to 65.7)
SecondaryPercentage of Participants Who Achieved HiSCR50 at Week 54 for Participants Who Took Only Povorcitinib

HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
Baseline; Week 54
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HiSCR50 at Week 54 for Participants Who Took Only Povorcitinib
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants Who Achieved HiSCR50 at Week 54 for Participants Who Took Only Povorcitinib—67.5 (58.1 to 76.0)57.3 (48.1 to 66.1)
SecondaryPercentage of Participants Who Achieved HiSCR50 at Week 54 During the Extension Period

HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
Baseline; Week 54
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HiSCR50 at Week 54 During the Extension Period
percentage of participantsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Percentage of Participants Who Achieved HiSCR50 at Week 54 During the Extension Period64.3 (50.4 to 76.6)71.4 (57.8 to 82.7)
SecondaryPercentage of Participants Who Achieved HiSCR75 at Week 54 for Participants Who Took Only Povorcitinib

HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
Baseline; Week 54
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HiSCR75 at Week 54 for Participants Who Took Only Povorcitinib
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants Who Achieved HiSCR75 at Week 54 for Participants Who Took Only Povorcitinib—57.0 (47.4 to 66.3)46.8 (37.8 to 55.9)
SecondaryPercentage of Participants Who Achieved HiSCR75 at Week 54 During the Extension Period

HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
Baseline; Week 54
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HiSCR75 at Week 54 During the Extension Period
percentage of participantsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Percentage of Participants Who Achieved HiSCR75 at Week 54 During the Extension Period48.2 (34.7 to 62.0)44.6 (31.3 to 58.5)
SecondaryPercentage of Participants With Flare by Week 54 for Participants Who Took Only Povorcitinib

Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.

Time frame:
Baseline; up to Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Flare by Week 54 for Participants Who Took Only Povorcitinib
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants With Flare by Week 54 for Participants Who Took Only Povorcitinib—22.3 (16.7 to 28.6)23.0 (17.4 to 29.4)
SecondaryPercentage of Participants With Flare at Week 54 During the Extension Period

Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline.

Time frame:
Baseline; up to Week 54
Reported as:
Number · percentage of participants
Percentage of Participants With Flare at Week 54 During the Extension Period
percentage of participantsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Percentage of Participants With Flare at Week 54 During the Extension Period15.7 (8.9 to 25.0)9.8 (4.6 to 17.8)
SecondaryPercentage of Participants Who Achieved Skin Pain NRS30 at Week 54 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib

Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.

Time frame:
Baseline; Week 54
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib
percentage of participantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib—59.5 (47.9 to 70.4)64.5 (52.7 to 75.1)
SecondaryPercentage of Participants Who Achieved Skin Pain NRS30 at Week 54 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3

Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed.

Time frame:
Baseline; Week 54
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3
percentage of participantsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 366.7 (49.0 to 81.4)54.1 (36.9 to 70.5)
SecondaryPercentage of Participants Who Achieved Maintenance of HiSCR50 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib

Maintenance of response is defined as achieving HiSCR50 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
up to 42 weeks (from end of Week 12 to end of Week 54)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Maintenance of HiSCR50 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib
percentage of participantsPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Week 1584.3 (74.7 to 91.4)79.1 (69.0 to 87.1)
Week 1884.0 (74.1 to 91.2)79.8 (69.6 to 87.7)
Week 2476.9 (66.0 to 85.7)77.5 (66.8 to 86.1)
Week 3074.0 (62.4 to 83.5)74.7 (63.3 to 84.0)
Week 3685.1 (74.3 to 92.6)73.2 (61.4 to 83.1)
Week 4278.1 (66.0 to 87.5)68.2 (55.6 to 79.1)
Week 4880.3 (68.2 to 89.4)71.6 (59.3 to 82.0)
Week 5473.8 (60.9 to 84.2)70.8 (58.2 to 81.4)
SecondaryPercentage of Participants Who Achieved Maintenance of HiSCR75 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib

Maintenance of response is defined as achieving HiSCR75 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count.

Time frame:
up to 42 weeks (from end of Week 12 to end of Week 54)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Maintenance of HiSCR75 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib
percentage of participantsPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Week 1578.0 (64.0 to 88.5)80.7 (68.1 to 90.0)
Week 1885.1 (71.7 to 93.8)74.5 (61.0 to 85.3)
Week 2476.6 (62.0 to 87.7)69.8 (55.7 to 81.7)
Week 3073.3 (58.1 to 85.4)62.0 (47.2 to 75.3)
Week 3676.2 (60.5 to 87.9)66.0 (50.7 to 79.1)
Week 4282.5 (67.2 to 92.7)59.1 (43.2 to 73.7)
Week 4871.1 (54.1 to 84.6)60.0 (44.3 to 74.3)
Week 5468.4 (51.3 to 82.5)65.9 (50.1 to 79.5)
SecondaryPlacebo-controlled Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Placebo-controlled Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Placebo-controlled Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)99130131
SecondaryPlacebo-controlled Period: Number of Participants With ≥Grade 3 TEAEs

A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Placebo-controlled Period: Number of Participants With ≥Grade 3 TEAEs
ParticipantsPlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Placebo-controlled Period: Number of Participants With ≥Grade 3 TEAEs586
SecondaryExtension Period: Number of Participants With TEAEs

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.

Time frame:
up to 46 weeks (from end of Week 12 to end of Week 58)
Reported as:
Count of participants · Participants
Extension Period: Number of Participants With TEAEs
ParticipantsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Extension Period: Number of Participants With TEAEs6371
SecondaryExtension Period: Number of Participants With ≥Grade 3 TEAEs

A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to 46 weeks (from end of Week 12 to end of Week 58)
Reported as:
Count of participants · Participants
Extension Period: Number of Participants With ≥Grade 3 TEAEs
ParticipantsPlacebo to Povorcitinib 45 mg QDPlacebo to Povorcitinib 75 mg QD
Extension Period: Number of Participants With ≥Grade 3 TEAEs57
SecondaryOverall Study Period: Number of Participants Who Took Only Povorcitinib With TEAEs

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug.

Time frame:
up to Week 58
Reported as:
Count of participants · Participants
Overall Study Period: Number of Participants Who Took Only Povorcitinib With TEAEs
ParticipantsPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Overall Study Period: Number of Participants Who Took Only Povorcitinib With TEAEs164171
SecondaryOverall Study Period: Number of Participants Who Took Only Povorcitinib With ≥Grade 3 TEAEs

A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Time frame:
up to Week 58
Reported as:
Count of participants · Participants
Overall Study Period: Number of Participants Who Took Only Povorcitinib With ≥Grade 3 TEAEs
ParticipantsPovorcitinib 45 mg QDPovorcitinib 75 mg QD
Overall Study Period: Number of Participants Who Took Only Povorcitinib With ≥Grade 3 TEAEs1817

Adverse events

Collected over Adverse events (AEs) were reported from the first dose of study treatment up to approximately 58 weeks for povorcitinib and for up to 16 weeks for placebo.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PC Period: Povorcitinib 45 mg QD0/208 (0%)4/208 (1.9%)61/208 (29.3%)
PC Period: Povorcitinib 75 mg QD0/207 (0%)4/207 (1.9%)75/207 (36.2%)
PC Period: Placebo0/203 (0%)5/203 (2.5%)38/203 (18.7%)
Any Povorcitinib 45 mg0/298 (0%)19/298 (6.4%)142/298 (47.7%)
Any Povorcitinib 75 mg0/299 (0%)19/299 (6.4%)150/299 (50.2%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPC Period: Povorcitinib 45 mg QDPC Period: Povorcitinib 75 mg QDPC Period: PlaceboAny Povorcitinib 45 mgAny Povorcitinib 75 mg
HidradenitisSkin and subcutaneous tissue disorders2/2082/2070/2037/2985/299
CellulitisInfections and infestations0/2080/2070/2031/2982/299
AppendicitisInfections and infestations0/2080/2071/2030/2980/299
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2080/2071/2030/2980/299
HypertriglyceridaemiaMetabolism and nutrition disorders0/2080/2071/2030/2980/299
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/2080/2071/2030/2980/299
Scrotal cellulitisInfections and infestations0/2080/2071/2030/2980/299
DepressionPsychiatric disorders0/2081/2070/2030/2981/299
Faeces discolouredGastrointestinal disorders0/2081/2070/2030/2981/299
Pyoderma gangrenosumSkin and subcutaneous tissue disorders0/2081/2070/2030/2981/299
Most frequent other events
Most frequent other events
EventPC Period: Povorcitinib 45 mg QDPC Period: Povorcitinib 75 mg QDPC Period: PlaceboAny Povorcitinib 45 mgAny Povorcitinib 75 mg
AcneSkin and subcutaneous tissue disorders18/20824/20711/20349/29863/299
Upper respiratory tract infectionInfections and infestations12/20812/2076/20327/29833/299
NasopharyngitisInfections and infestations10/20816/2079/20328/29832/299
COVID-19Infections and infestations8/20811/2077/20322/29828/299
HeadacheNervous system disorders14/20816/2077/20322/29826/299
Blood creatine phosphokinase increasedInvestigations7/2086/2071/20317/29813/299
HypertensionVascular disorders4/2083/2071/20310/29817/299
InfluenzaInfections and infestations3/2084/2071/20315/29812/299
DiarrhoeaGastrointestinal disorders3/2084/2071/20310/29815/299

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QDTotal
Mean37.8 ± 11.7137.4 ± 11.4335.6 ± 10.9736.9 ± 11.39
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QDTotal
Female110134123367
Male937485252
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QDTotal
Hispanic or Latino21323184
Not Hispanic or Latino174168163505
Unknown or Not Reported881430
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPovorcitinib 45 mg QDPovorcitinib 75 mg QDTotal
White162156159477
Black/African American21302576
Asian73010
American Indian/Alaska Native1113
Not Reported581326
Unknown0112
Pakistani1102
Bengali1001
Captured as "Hispanic" in Database1001
Arab1001
Mixed Race1001
Black and White1001
Middle Eastern1023
Persian0101
Indian0101
Captured as "First Nations" in Database0101
South American0101
Puerto Rican0112
Mexican0314
Aboriginal0022
Captured as "Hispanic or Latino" in Database0011
Captured as "Latina" in Database0011
Half Asian, Half Black0011
08

Study locations

101 sites
  • Investigative Site US240
    Scottsdale, Arizona 85255, United States
  • Investigative Site US237
    Scottsdale, Arizona 85259, United States
  • Investigative Site US214
    Arkansas City, Arkansas 72758, United States
  • Investigative Site US242
    Fayetteville, Arkansas 72703, United States
  • Investigative Site US223
    Los Angeles, California 90033, United States
  • Investigative Site US226
    San Diego, California 92103, United States
  • Investigative Site US222
    San Francisco, California 94118, United States
  • Investigative Site US233
    Washington D.C., District of Columbia 20060, United States
  • Investigative Site US228
    Brandon, Florida 33511, United States
  • Investigative Site US227
    Margate, Florida 33063, United States
  • Investigative Site US204
    Miami, Florida 33125, United States
  • Investigative Site US236
    Miami, Florida 33173, United States
  • Investigative Site US200
    Ocala, Florida 34470, United States
  • Investigative Site US201
    Tampa, Florida 33613, United States
  • Investigative Site US220
    West Dundee, Illinois 60118, United States
  • Investigative Site US206
    Indianapolis, Indiana 46250, United States
  • Investigative Site US241
    Iowa City, Iowa 52242, United States
  • Investigative Site US209
    Louisville, Kentucky 40241, United States
  • Investigative Site US207
    Metairie, Louisiana 70006, United States
  • Investigative Site US229
    New Orleans, Louisiana 70115, United States
  • Investigative Site US224
    Baltimore, Maryland 21224, United States
  • Investigative Site US208
    Beverly, Massachusetts 01915, United States
  • Investigative Site US221
    Quincy, Massachusetts 02169, United States
  • Investigative Site US213
    Detroit, Michigan 48084, United States
  • Investigative Site US217
    Waterford, Michigan 48328, United States
  • Investigative Site US212
    Minneapolis, Minnesota 55455, United States
  • Investigative Site US239
    Omaha, Nebraska 68144, United States
  • Investigative Site US230
    Hightstown, New Jersey 08520, United States
  • Investigative Site US202
    New York, New York 10003, United States
  • Investigative Site US210
    Rochester, New York 14642, United States
  • Investigative Site US205
    Chapel Hill, North Carolina 27516, United States
  • Investigative Site US215
    Bexley, Ohio 43209, United States
  • Investigative Site US203
    Columbus, Ohio 43210, United States
  • Investigative Site US232
    Murfreesboro, Tennessee 37130, United States
  • Investigative Site US235
    Arlington, Texas 76011, United States
  • Investigative Site US218
    Bellaire, Texas 77401, United States
  • Investigative Site US238
    Pflugerville, Texas 78660, United States
  • Investigative Site US234
    San Antonio, Texas 78213, United States
  • Investigative Site AU205
    Kogarah, New South Wales 02217, Australia
  • Investigative Site AU203
    Kotara, New South Wales 02289, Australia
  • Investigative Site AU200
    Liverpool, New South Wales 02170, Australia
  • Investigative Site AU202
    Benowa, Queensland 04217, Australia
  • Investigative Site AU206
    Woolloongabba, Queensland 04102, Australia
  • Investigative Site AU207
    Woolloongabba, Queensland 04102, Australia
  • Investigative Site AU201
    Carlton, Victoria 03053, Australia
  • Investigative Site AU204
    Melbourne, Victoria 03002, Australia
  • Investigative Site BG203
    Sofia, 01407, Bulgaria
  • Investigative Site BG202
    Sofia, 01463, Bulgaria
  • Investigative Site BG200
    Sofia, 01510, Bulgaria
  • Investigative Site BG204
    Sofia, 01606, Bulgaria
  • Investigative Site BG201
    Stara Zagora, 06000, Bulgaria
  • Investigative Site CA202
    Calgary, Alberta T3E 0B2, Canada
  • Investigative Site CA204
    Edmonton, Alberta T6G 1C3, Canada
  • Investigative Site CA200
    Surrey, British Columbia V3V 0C6, Canada
  • Investigative Site CA205
    Fredericton, New Brunswick E3B 1G9, Canada
  • Investigative Site CA207
    Mississauga, Ontario L4W 0C2, Canada
  • Investigative Site CA208
    Richmond Hill, Ontario L4C 9M7, Canada
  • Investigative Site CA206
    Saint-Jérôme, Quebec J7Z 7E2, Canada
  • Investigative Site CA203
    St. John's, A1A 4Y3, Canada
  • Investigative Site DK200
    Århus N, 08200, Denmark
  • Investigative Site DK201
    Roskilde, 04000, Denmark
  • Investigative Site FR200
    Antony, 92160, France
  • Investigative Site FR205
    Dijon, 21000, France
  • Investigative Site FR204
    Lyon, 69003, France
  • Investigative Site FR203
    Nice, 06200, France
  • Investigative Site FR206
    Reims, 51100, France
  • Investigative Site FR202
    Rouen, 76031, France
  • Investigative Site FR201
    Toulon, 83000, France
  • Investigative Site US225
    Frankfurt am Main, MA 60590, Germany
  • Investigative Site DE202
    Berlin, 10117, Germany
  • Investigative Site DE203
    Bochum, 44791, Germany
  • Investigative Site DE201
    Dessau, 06847, Germany
  • Investigative Site DE207
    Erlangen, 91054, Germany
  • Investigative Site DE208
    Göttingen, 37075, Germany
  • Investigative Site DE205
    Heidelberg, 69120, Germany
  • Investigative Site DE200
    Kiel, 24105, Germany
  • Investigative Site DE204
    Lübeck, 23538, Germany
  • Investigative Site DE206
    Mainz, 55131, Germany
  • Investigative Site IT200
    Ancona, 60126, Italy
  • Investigative Site IT204
    Brescia, 25124, Italy
  • Investigative Site IT207
    Catania, 95123, Italy
  • Investigative Site IT202
    Milan, 20122, Italy
  • Investigative Site IT203
    Naples, 80131, Italy
  • Investigative Site IT206
    Pisa, 56126, Italy
  • Investigative Site IT205
    Roma, 00168, Italy
  • Investigative Site IT201
    Rozzano, 20089, Italy
  • Investigative Site PL203
    Lublin, 20573, Poland
  • Investigative Site PL200
    Rzeszów, 35-055, Poland
  • Investigative Site PL201
    Warsaw, 02-507, Poland
  • Investigative Site PL202
    Warsaw, 02-962, Poland
  • Investigative Site ES203
    Alicante, 03010, Spain
  • Investigative Site ES202
    Las Palmas de Gran Canaria, 35019, Spain
  • Investigative Site ES204
    Madrid, 28005, Spain
  • Investigative Site ES201
    Madrid, 28007, Spain
  • Investigative Site ES205
    Madrid, 28040, Spain
  • Investigative Site ES200
    Manises, 46940, Spain
  • Investigative Site GB202
    Birmingham, B15 2GW, United Kingdom
  • Investigative Site GB200
    Dudley, DY1 2HQ, United Kingdom
  • Investigative Site GB201
    Leeds, LS1 3EX, United Kingdom
  • Investigative Site GB204
    London, SE1 7EH, United Kingdom

Showing the first 100 of 101 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Porter ML, Martorell A, Sayed CJ, Bechara FG, Lev-Tov H, Hsiao JL, Frew JW, Reguiai Z, Gooderham MJ, Goldfarb N, van der Zee HH, Del Marmol V, Marzano AV, Ehst BD, Ackerman LS, Hayama K, Tian C, Kelley J, Zhen H, Kirby JS, Brown K, Santos LL, Zouboulis CC. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. Nat Med. 2026 Aug;32(8):3071-3081. doi: 10.1038/s41591-026-04534-z. Epub 2026 Jul 23. PubMed 42493571 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Jan 2025, 22 months.

Results were first posted in Nov 2026, 1 year 9 months after primary completion. A results delay was requested in Jan 2026.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2022
First posted
Nov 17, 2022
StartActual
Feb 22, 2023
Primary completionActual
Jan 7, 2025
CompletionActual
Nov 21, 2025
Results delay requested
Jan 6, 2026
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProportionPercentage of participants who achieveParticipants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCRHiSCR50) at Week 12Time frame: Week 12 → Baseline; Week 12
Nov 5, 2026
Documents
Secondary outcomes
15 edited, 15 added, 20 more
What changed in the outcomes
  • EditedProportionPercentage of participants with flareParticipants With Flare by Week 12Time frame: 12 Weeks → Baseline; Week 12
  • EditedProportionPercentage of participants withParticipants With at Least a ≥ 3-point decreaseDecrease in Skin Pain NumericNumerical Rating Scale (NRS) score among participants with baselineScore at Week 12 Among Participants With a Baseline Skin Pain NRS scoreScore ≥ 3Time frame: Week 12 → Baseline; Week 12
  • EditedProportionPercentage of participants who achieveParticipants Who Achieved Skin Pain NRS30 at Week 12 among participants with baselineAmong Participants With a Baseline Skin Pain NRS score ≥Score of at Least 3.Time frame: Week 12 → Baseline; Week 12
  • EditedProportionPercentage of participants withParticipants With at Least a ≥ 4-point increase from baselineIncrease From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scoreScore at Week 12Time frame: Week 12 → Baseline; Week 12
  • EditedMean change from baselineChange From Baseline in Dermatology Life Quality Index (DLQI) scoreScore at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: 54 weeks → Baseline; up to Week 54
  • EditedMean change from baselineChange From Baseline in abscess countAbscess Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
  • EditedPercentage change from baselineChange From Baseline in abscess countAbscess Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
  • EditedMean change from baselineChange From Baseline in inflammatory nodule countInflammatory Nodule Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
  • EditedPercentage change from baselineChange From Baseline in inflammatory nodule countInflammatory Nodule Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
  • EditedMean change from baselineChange From Baseline in draining tunnel countDraining Tunnel Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
  • EditedPercentage change from baselineChange From Baseline in draining tunnel countDraining Tunnel Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
  • EditedExtension Period: ProportionNumber of participants who achieve HiSCRParticipants With TEAEsTime frame: Week 24 → up to 46 weeks (from end of Week 12 to end of Week 58)
  • EditedExtension Period: ProportionNumber of participants with flareParticipants With ≥Grade 3 TEAEsTime frame: From Week 12 through Week 24 → up to 46 weeks (from end of Week 12 to end of Week 58)
  • EditedExtension Period: ProportionPercentage of participants who achievedParticipants Who Achieved Skin Pain NRS30 among participants with baselineat Week 24 Among Participants With Baseline Skin Pain NRS score ≥Score of at Least 3. and Who Took Only PovorcitinibTime frame: Week 24 → Baseline; Week 24
  • EditedExtension Period: ProportionPercentage of participants who achievedParticipants Who Achieved Skin Pain NRS30 among participants with baselineat Week 24 During the Extension Period Among Participants With Baseline Skin Pain NRS score ≥Score of at Least 3.Time frame: Week 54 → Baseline; Week 24
  • AddedPercentage of Participants Who Achieved HiSCR75 at Week 12Time frame: Baseline; Week 12
  • AddedMean Change From Baseline in DLQI Score at Each Visit During the Extension PeriodTime frame: Baseline; up to Week 54
  • AddedMean Change From Baseline in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
  • AddedPercentage Change From Baseline (PCFB) in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
  • AddedMean Change From Baseline in Inflammatory Nodule Count at Each Visit at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
  • AddedPercentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
  • AddedMean Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
  • AddedPercentage Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
  • AddedPercentage of Participants Who Achieved HiSCR50 at Week 24 for Participants Who Took Only PovorcitinibTime frame: Baseline; Week 24
  • AddedPercentage of Participants Who Achieved HiSCR50 at Week 24 During the Extension PeriodTime frame: Baseline; Week 24
  • AddedPercentage of Participants Who Achieved HiSCR75 at Week 24 for Participants Who Took Only PovorcitinibTime frame: Baseline; Week 24
  • AddedPercentage of Participants Who Achieved HiSCR75 at Week 24 During the Extension PeriodTime frame: Baseline; Week 24
  • AddedPercentage of Participants With Flare by Week 24 for Participants Who Took Only PovorcitinibTime frame: Baseline; up to Week 24
  • AddedPercentage of Participants With Flare by Week 24 During the Extension PeriodTime frame: Baseline; up to Week 24
  • AddedPercentage of Participants Who Achieved HiSCR50 at Week 54 for Participants Who Took Only PovorcitinibTime frame: Baseline; Week 54
  • …and 20 more, on the record history on ClinicalTrials.gov ↗
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProportionPercentage of participants who achieveParticipants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCRHiSCR50) at Week 12Time frame: Week 12 → Baseline; Week 12
    Secondary outcomes 15 edited, 15 added, 20 more
    What changed in the outcomes
    • EditedProportionPercentage of participants with flareParticipants With Flare by Week 12Time frame: 12 Weeks → Baseline; Week 12
    • EditedProportionPercentage of participants withParticipants With at Least a ≥ 3-point decreaseDecrease in Skin Pain NumericNumerical Rating Scale (NRS) score among participants with baselineScore at Week 12 Among Participants With a Baseline Skin Pain NRS scoreScore ≥ 3Time frame: Week 12 → Baseline; Week 12
    • EditedProportionPercentage of participants who achieveParticipants Who Achieved Skin Pain NRS30 at Week 12 among participants with baselineAmong Participants With a Baseline Skin Pain NRS score ≥Score of at Least 3.Time frame: Week 12 → Baseline; Week 12
    • EditedProportionPercentage of participants withParticipants With at Least a ≥ 4-point increase from baselineIncrease From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scoreScore at Week 12Time frame: Week 12 → Baseline; Week 12
    • EditedMean change from baselineChange From Baseline in Dermatology Life Quality Index (DLQI) scoreScore at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: 54 weeks → Baseline; up to Week 54
    • EditedMean change from baselineChange From Baseline in abscess countAbscess Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
    • EditedPercentage change from baselineChange From Baseline in abscess countAbscess Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
    • EditedMean change from baselineChange From Baseline in inflammatory nodule countInflammatory Nodule Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
    • EditedPercentage change from baselineChange From Baseline in inflammatory nodule countInflammatory Nodule Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
    • EditedMean change from baselineChange From Baseline in draining tunnel countDraining Tunnel Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
    • EditedPercentage change from baselineChange From Baseline in draining tunnel countDraining Tunnel Count at Each Visit During the Extension PeriodTime frame: 54 weeks → Baseline; up to Week 54
    • EditedExtension Period: ProportionNumber of participants who achieve HiSCRParticipants With TEAEsTime frame: Week 24 → up to 46 weeks (from end of Week 12 to end of Week 58)
    • EditedExtension Period: ProportionNumber of participants with flareParticipants With ≥Grade 3 TEAEsTime frame: From Week 12 through Week 24 → up to 46 weeks (from end of Week 12 to end of Week 58)
    • EditedExtension Period: ProportionPercentage of participants who achievedParticipants Who Achieved Skin Pain NRS30 among participants with baselineat Week 24 Among Participants With Baseline Skin Pain NRS score ≥Score of at Least 3. and Who Took Only PovorcitinibTime frame: Week 24 → Baseline; Week 24
    • EditedExtension Period: ProportionPercentage of participants who achievedParticipants Who Achieved Skin Pain NRS30 among participants with baselineat Week 24 During the Extension Period Among Participants With Baseline Skin Pain NRS score ≥Score of at Least 3.Time frame: Week 54 → Baseline; Week 24
    • AddedPercentage of Participants Who Achieved HiSCR75 at Week 12Time frame: Baseline; Week 12
    • AddedMean Change From Baseline in DLQI Score at Each Visit During the Extension PeriodTime frame: Baseline; up to Week 54
    • AddedMean Change From Baseline in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
    • AddedPercentage Change From Baseline (PCFB) in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
    • AddedMean Change From Baseline in Inflammatory Nodule Count at Each Visit at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
    • AddedPercentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
    • AddedMean Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
    • AddedPercentage Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)Time frame: Baseline; up to Week 54
    • AddedPercentage of Participants Who Achieved HiSCR50 at Week 24 for Participants Who Took Only PovorcitinibTime frame: Baseline; Week 24
    • AddedPercentage of Participants Who Achieved HiSCR50 at Week 24 During the Extension PeriodTime frame: Baseline; Week 24
    • AddedPercentage of Participants Who Achieved HiSCR75 at Week 24 for Participants Who Took Only PovorcitinibTime frame: Baseline; Week 24
    • AddedPercentage of Participants Who Achieved HiSCR75 at Week 24 During the Extension PeriodTime frame: Baseline; Week 24
    • AddedPercentage of Participants With Flare by Week 24 for Participants Who Took Only PovorcitinibTime frame: Baseline; up to Week 24
    • AddedPercentage of Participants With Flare by Week 24 During the Extension PeriodTime frame: Baseline; up to Week 24
    • AddedPercentage of Participants Who Achieved HiSCR50 at Week 54 for Participants Who Took Only PovorcitinibTime frame: Baseline; Week 54
    • …and 20 more, on the record history on ClinicalTrials.gov ↗
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05620836
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Nov 17, 2022
Start date
Feb 22, 2023
Primary completion
Jan 7, 2025
Completion
Nov 21, 2025
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion